

Current CMV Treatment Options and Management Strategies



AMMI Canada/Merck Co-developed Accredited Learning Activity

Date: Thursday, May 4, 2017


Location: Sheraton Centre Toronto Grand Ballroom West

Time: 12:40 – 2:40 PM
(Registration & Lunch from 12:40 – 1:10 PM)

WHILE ATTENDING the AMMI Canada – CACMID Annual Conference, you are cordially invited to attend an AMMI Canada/Merck Co-developed Accredited Learning Activity. Pre-registration is required, to a maximum of 200 people. No walk-ins will be permitted once the maximum is reached.

[REGISTER NOW](#)

Moderator



Christopher Lowe
MD, MSc, D(ABMM), FRCPC

Medical Microbiologist
Infection Prevention and Control Physician
Department of Pathology and
Laboratory Medicine
Providence Health Care
Vancouver, BC

Speakers



Tony Mazzulli
MD, FRCPC, FACP

Microbiologist-in-Chief
Department of Microbiology
Mount Sinai Hospital
Toronto, ON



Alissa Wright
MD, FRCPC, MSc

Clinical Assistant Professor
Director, Transplant Infectious
Disease Program
Division of Infectious Disease
Vancouver, BC

Agenda

- | | |
|-----------------|--|
| 12:40 – 1:10 PM | Registration and Lunch |
| 1:10 – 1:15 PM | Welcome Remarks and Introduction
(Christopher Lowe, MD) |
| 1:15 – 1:45 PM | CMV Diagnostic Strategies:
Current and Future
(Tony Mazzulli, MD)
Objectives: <ul style="list-style-type: none">• Cite current tests available for the diagnosis and management of CMV disease in SOT and HSCT patients including resistance testing• Interpret results of resistance testing• Recognize future testing options |
| 1:45 – 2:15 PM | CMV Treatment and the Dilemma of Resistance
(Alissa Wright, MD)
Objectives: <ul style="list-style-type: none">• Review the current approaches to treatment of CMV disease for SOT and HSCT patients• Discuss treatment challenges associated with patients with CMV resistance |
| 2:15 – 2:40 PM | Discussion and Wrap-Up |

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck and was planned to achieve scientific integrity, objectivity and balance.

This program is supported by an educational grant from MERCK



Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.